Consequently, ERα antagonists like tamoxifen and raloxifene are currently used as frontline pharmacological interventions in ERα-positive breast cancer in order to inhibit the mitogenic stimulation of estrogens [5]. The gene discussed is ESR1; the disease is breast carcinoma.